Glenmark Life Sciences rebranded as Alivus Life Sciences
News

Glenmark Life Sciences rebranded as Alivus Life Sciences

The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space

  • By IPP Bureau | January 19, 2025

Glenmark Life Sciences, a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas, announces its change of identity to Alivus Life Sciences, marking an exciting new chapter in its journey.

This is consequent to the acquisition by Nirma Limited, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals.

The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey.

The official website is now alivus.com, providing comprehensive information about the company’s updated brand identity, services and initiatives.

This rebranding to Alivus Life Sciences marks an important milestone in the company’s journey. It symbolizes our commitment to enhancing services for our customers, stakeholders, and employees. While the company’s name has changed, its dedication to quality and innovation remains steadfast. 

The company’s four manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh with a total installed capacity of 1,424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe).

Upcoming E-conference

Other Related stories

Startup

Digitization